R 152010Z JUL 20
MARADMIN 402/20
MSGID/GENADMIN/CMC WASHINGTON DC DMCS//
SUBJ/COVID-19 CONVALESCENT PLASMA//
REF/A/DOC/DOD/8JUN20//
AMPN/REF A IS DEPARTMENT OF DEFENSE COVID-19 CONVALESCENT PLASMA COLLECTION CAMPAIGN INFORMATION.//
GENTEXT/REMARKS/1.  Purpose.  This message provides information on the voluntary COVID-19 convalescent plasma donation program.
2.  Background.  Since the beginning of the COVID-19 global pandemic, over 3 million Americans have tested positive for COVID-19.  To date, there has been no definitive treatment or vaccine developed; however, the Food and Drug Administration has authorized the use of COVID-19 convalescent plasma (CCP) as an investigational treatment for patients with moderate to severe COVID-19 infections.  CCP is derived from either whole blood collections or apheresis plasma collections from COVID-19 patients who have recovered from the disease.  The Department of Defense has established a goal to collect 10,000 COVID-19 CCP units by September 30, 2020 to sustain the readiness of the Force.
3.  Execution.
3.A.  Commander’s Intent.
3.A.1.  Purpose.  To promulgate widest dissemination of information to Marine Corps personnel for voluntary participation in support Department of Defense CCP collection efforts.
3.A.2.  Method.  The Armed Service Blood Program (ASBP) Blood Donation Centers (BDCs) will be contacting all beneficiaries who have tested positive for COVID-19.  Additionally, multiple blood donation drives will be scheduled by local BDCs to optimize collection of whole blood donations.  Donations to the ASBP are strictly voluntary; however, Commanders are highly encouraged to make their personnel aware of local donation options and provide time for those who choose to donate at their local BDC.  All donations will be screened for SARS-CoV-2 antibodies.  Donors who are positive for the SARS-CoV-2 antibodies will be contacted by the local BDC and given information about voluntary apheresis plasma donation.  A donor with newly discovered SARS-CoV-2 antibodies does not require restriction of movement.  The BDCs will report aggregate donor collection information only, with no specific reporting of Marine Corps personnel who have donated CCP.
3.A.3.  End State.  The Marine Corps is committed to supporting the Department of Defense’s contribution to investigational treatment for COVID-19 patients that may benefit from CCB.
4.  Points of Contact.  Local BDCs will have the latest information regarding the scheduled blood drive collection events.  Any other questions or concerns regarding CCP may be directed to HQMC Health Services at (703) 604-4602 or email HQMC_MEDICAL@usmc.mil.
5.  This MARADMIN has been coordinated with the Armed Services Blood Program and Director, Health Services.
6.  Release authorized by Lieutenant General John J. Broadmeadow, Director, Marine Corps Staff.//